Vol. 3 No. 4 (2023)
Reimbursement Recommendations

Brexucabtagene Autoleucel (Tecartus)

decorative image

Published April 17, 2023

Key Messages

  • CADTH recommends that Tecartus be reimbursed by public drug plans for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) if certain conditions are met.
  • Tecartus should only be covered to treat adult patients who have B-cell precursor ALL whose disease never achieved remission from previous treatments, returned within 1 year after the first remission, returned or did not respond after 2 or more treatments, or returned or did not respond after an allogeneic stem cell transplant (alloSCT).
  • Tecartus should only be reimbursed for patients who have not already received a chimeric antigen receptor (CAR) T-cell therapy, are in relatively good health, do not have leukemia in the central nervous system (CNS), and the cost of Tecartus is reduced. Tecartus should be prescribed and administered by clinicians with expertise in leukemia and cellular therapy or SCT in a hospital setting with adequate resources to perform the procedure and manage side effects.